Last Updated on December 4, 2024 by The Health Master
CDSCO
AstraZeneca Pharma India Ltd has made significant strides in the fight against cancer. The company recently announced that it has received approval from the Central Drugs Standard Control Organisation (CDSCO) to import and distribute Olaparib (brand name Lynparza) in India.
What is Olaparib ?
Olaparib is a targeted cancer therapy that works by blocking a specific protein involved in cancer cell growth and repair.
This innovative approach makes it a promising treatment option for various types of cancer.
Indication for Use
The CDSCO’s approval of Olaparib is specifically for the maintenance treatment of adult patients with advanced or recurrent endometrial cancer.
This means that the drug can be used to help prevent the cancer from returning or worsening after initial treatment with Durvalumab and platinum-based chemotherapy.
A Step Forward in Cancer Treatment
This approval marks a significant milestone for cancer patients in India.
By providing access to advanced treatments like Olaparib, AstraZeneca is helping to improve patient outcomes and quality of life.
Key Takeaways:
- AstraZeneca India has received CDSCO approval for Olaparib.
- Olaparib is a targeted cancer therapy for advanced or recurrent endometrial cancer.
- The drug works by blocking a specific protein involved in cancer cell growth and repair.
- This approval brings hope to cancer patients in India.
-
What is Olaparib?
Olaparib is the generic name for the drug, while Lynparza is the brand name.
-
How does Olaparib work?
Olaparib targets a specific protein involved in DNA repair, preventing cancer cells from repairing themselves.
-
Is Olaparib a new drug?
While it’s relatively new to the Indian market, Olaparib has been used in other countries for several years.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
Disclaimer: This content, provides generic information only. It is in no way a substitute for a qualified medical opinion. Always consult a specialist or your own doctor for more information. The Health Master does not claim responsibility for this information.
CDSCO Panel nod granted for Lumateperone Capsule
CDSCO Recruitment Rules for Medical Device Officers: A Closer Look
CDSCO Panel nod for Clinical Trial of Ranibizumab Solution for Injection
CDSCO Nod granted to Conduct Clinical Trial of Ruxolitinib cream
CDSCO Gains Global Recognition: Milestone for Indian Medical Device Industry
CDSCO approval granted for Durvalumab therapy with specified indication
Drug recall: Lupin recalls 6 lakh bottles of this BP Drug
FSSAI: Food Labelling and Display – Chapter-12
USFDA issued Form 483 with 5 observations to Alembic
India to ease Regulations for Stem Cell and Gene Therapy product manufacturing
State Demands National Portal to Track Fake Drugs
NPPA recalculates Ceiling Price of Atorvastatin 10mg
Fire explosion at Aurore Pharmaceuticals
Drug recall: Cipla recalls over 1.8k boxes of this drug
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
